The study team observed a striking reduction in pan-neuronal immunostaining in pancreata from people with cystic fibrosis and in CF ferrets. In human samples, pan-neuronal staining using Class III beta-tubulin (TUJ1) was reported as nearly absent by the authors; in ferrets, TUJ1 staining remained present but exhibited aberrant morphology and an abnormal distribution relative to wild-type controls. Micrographs presented in the full text illustrate TUJ1+ axonal processes in control pancreas juxtaposed to a sparse or mislocalized signal in CF specimens. The investigators reported that these changes coexisted with identifiable islets, indicating that neuronal loss or remodeling occurs in tissue that still contains endocrine cell populations.
The authors examined a parasympathetic nerve terminal marker, VAChT, to assess cholinergic innervation. VAChT immunostaining was described as nearly absent in both human and ferret CF pancreata. In control tissues, VAChT+ axons were seen adjacent to or interfacing with islets; those patterns were not observed in CF samples according to the reported images. Because pancreatic polypeptide (PP) secretion is known to be largely dependent on parasympathetic input, the loss of VAChT+ innervation provides a plausible mechanistic link to altered hormone dynamics in vivo.
Clinical physiological measures showed that young humans and ferrets with CF had greatly impaired circulating pancreatic polypeptide responses to an oral glucose challenge. The authors reported time-course data and incremental AUC for early PP responses (iAUC30). Despite the blunted in vivo PP signal, pancreatic histology revealed an abundance of PP-positive cells in CF tissue. Perfusion experiments using isolated CF ferret islets produced a key divergence: when perifused ex vivo, CF ferret islets secreted PP normally. The authors interpreted these paired observations as evidence that the endocrine cells retained secretory competence, whereas extrinsic neural inputs necessary for physiologic stimulation in vivo were compromised. This pattern suggests a disruption of neuroendocrine communication rather than an intrinsic failure of PP-producing cells.
The study team tested whether delaying the onset of exocrine pancreatic disease altered neural outcomes by treating CFTRG551D homozygous ferrets with a CFTR modulator early in life. When exocrine pancreatic disease was delayed until after the first month by modulator administration, pancreatic neuronal markers were preserved and PP secretory responsiveness to oral glucose was restored in those animals, as the authors reported. This experimental arm links early exocrine injury to subsequent neuronal loss and functional endocrine impairment, and it indicates that modifying the timing of exocrine disease can avert neural remodeling in this animal model.
The abstract and figure legends summarize key observations, but the text provided here did not include full methodological detail. The source did not report, within the abstract excerpt shown, exact sample sizes for each experiment, the specific CFTR modulator dosing regimen used in ferrets, or the complete protocols for perifusion assays and immunostaining quantification. Readers should consult the full article for those data. The authors noted that images shown are representative (human micrographs from multiple pancreata; ferret images from several animals), but rigorous interpretation requires review of numerical quantitation, statistical methods, and the scope of biological replicates as reported in the full manuscript.
Limitations explicitly documented in the text provided include the species differences between ferret models and humans; while ferrets recapitulate important aspects of CF pancreatic disease, interspecies differences in neuroanatomy and disease progression may affect generalizability. The study design, as presented, supports a model in which early-life exocrine pancreatic injury drives loss or remodeling of pancreatic innervation, with consequent impairment of physiologic, parasympathetic-dependent hormone secretion. The authors observed that intrinsic islet secretory capacity for PP remained intact ex vivo, indicating that therapies targeting preservation of pancreatic innervation or prevention of early exocrine damage could plausibly protect neuroendocrine function — however, direct clinical translation and therapeutic dosing details were not provided in the abstract excerpt.
Final open questions recorded in the source material include whether similar neuronal loss affects other autonomic inputs beyond the parasympathetic axis, the precise temporal window in human infancy when pancreatic innervation becomes irreversibly altered, and the long-term functional consequences for insulin and glucagon regulation. The full text (PMC13624406) should be consulted for comprehensive methods, quantitative results, and statistical analyses.